Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry  by Hatse, Sigrid et al.
Mutations at the CXCR4 interaction sites for AMD3100 in£uence
anti-CXCR4 antibody binding and HIV-1 entry
Sigrid Hatsea;, Katrien Princena, Kurt Vermeirea, Lars-Ole Gerlachb, Mette M. Rosenkildeb,
Thue W. Schwartzb, Gary Bridgerc, Erik De Clercqa, Dominique Scholsa
aLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10,
B-3000 Leuven, Belgium
bThe Panum Institute, Copenhagen, Denmark
cAnorMed, Langley, BC, Canada
Received 11 March 2003; revised 14 May 2003; accepted 21 May 2003
First published online 4 June 2003
Edited by Hans-Dieter Klenk
Abstract The interaction of the CXCR4 antagonist AMD3100
with its target is greatly in£uenced by speci¢c aspartate residues
in the receptor protein, including Asp171 and Asp262. We have
now found that aspartate-to-asparagine substitutions at these
positions di¡erentially a¡ect the binding of four di¡erent anti-
CXCR4 monoclonal antibodies as well as the infectivity of di-
verse human immunode¢ciency virus type 1 (HIV-1) strains and
clinical isolates. Mutation of Asp262 strongly decreased the co-
receptor e⁄ciency of CXCR4 for wild-type but not for
AMD3100-resistant HIV-1 NL4.3. Thus, resistance of HIV-1
NL4.3 to AMD3100 is associated with a decreased dependence
of the viral gp120 on Asp262 of CXCR4, pointing to a di¡erent
mode of interaction of wild-type versus AMD3100-resistant vi-
rus with CXCR4.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The initial binding of the human immunode¢ciency virus
type 1 (HIV-1) envelope glycoprotein, gp120, to the cellular
receptor CD4 induces a conformational change in the gp120
complex, allowing it to interact with either of the chemokine
receptors CCR5 or CXCR4 [1^7]. The so-called R5 viruses,
isolated from patients early in the course of HIV-1 infection,
infect macrophages and T lymphocytes by using CCR5 as the
coreceptor [1]. On the other hand, CXCR4 is the major co-
receptor for the more pathogenic X4 HIV-1 strains that are
typically T cell-tropic and very often emerge during progres-
sion from the asymptomatic stage to immunode¢ciency
(AIDS) [8^10].
The bicyclam AMD3100 is the most potent and speci¢c
CXCR4 antagonist described to date [11^13]. The compound
strongly inhibits the replication of a wide variety of X4 HIV
strains and clinical isolates in vitro [11,12], and clearly showed
activity against X4 viruses in a phase II clinical trial in HIV-1-
infected individuals [14]. High-a⁄nity binding of AMD3100
to CXCR4 is based upon electrostatic interactions of the pos-
itively charged cyclam rings with Asp171 and Asp262, located
in transmembrane domain (TM) IV and TM VI, respectively,
at each end of the main ligand binding crevice of CXCR4
(Fig. 1) [15]. Mutation of these negatively charged aspartic
acid residues to neutral asparagines strongly impairs the
CXCR4 antagonism and antiviral activity of AMD3100 [16].
However, a few other negatively charged amino acid residues,
including the aspartates at positions 182 and 193 (Fig. 1),
have been identi¢ed as alternative or additional interaction
sites for AMD3100 ([17] and our unpublished data).
Given the unique receptor speci¢city and potent anti-HIV
activity of AMD3100, the amino acid residues that account
for the high-a⁄nity interaction between AMD3100 and
CXCR4 could also be important determinants in the interac-
tion of HIV-1 gp120 with CXCR4. Indeed, in analogy with
the net positive charge of AMD3100 and the natural CXCR4
ligand, stromal cell-derived factor 1 (SDF-1), the V3 loop of
X4 HIV gp120, is also enriched in basic amino acids [18]. We
have now investigated the impact of aspartate-to-asparagine
substitutions at positions 171, 182, 193 and 262 of CXCR4 on
anti-CXCR4 monoclonal antibody (mAb) binding and on
coreceptor activity of CXCR4 for diverse X4 or R5/X4
HIV-1 strains (i.e. NL4.3, IIIB, NDK, HE and the clinical
isolate CI-10), and for mutant viruses resistant to AMD3100,
SDF-1 or dextran sulfate.
2. Materials and methods
2.1. Viruses
The T-tropic (X4) HIV-1 molecular clone NL4.3 was obtained from
the National Institute of Allergy and Infectious Disease AIDS reagent
program (Bethesda, MD, USA). The X4 HIV-1 IIIB strain was a kind
gift from Dr. L. Montagnier (Pasteur Institute, Paris, France). The X4
HIV-1 strain NDK [19] was obtained from the Centralised Facility for
AIDS Reagents (UK Medical Research Council). The dual-tropic
(R5/X4) HIV-1 HE strain was initially isolated from a patient at
the University Hospital in Leuven, and had been routinely cultured
in MT-4 cells [20]. Virus stocks of the dual-tropic R5/X4 clinical
isolate CI-10 were generated by coculture of peripheral blood mono-
nuclear cells from a healthy donor with lymphocytes from an HIV-
infected person. Coreceptor usage of the viruses was determined by
viral replication assays in CXCR4- and CCR5-transfected U87.CD4
cells.
NL4.3 strains resistant to AMD3100 [21], SDF-1 [22] and dextran
sulfate [23] were selected as described previously, by passaging the
virus in MT-4 cells in the presence of progressively increasing concen-
trations of the antiviral agent.
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2.2. Cell cultures
Human astroglioma U87 cells expressing human CD4 (U87.CD4)
were kindly provided by Dr. Dan R. Littman (Skirball Institute of
Biomolecular Medicine, New York, NY, USA) and were transfected
with the di¡erent CXCR4 mutants as described previously [16]. The
stable transfectants were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium (Invitrogen, Paisley, UK) containing 10% fetal bovine serum
(FBS) (BioWhittaker Europe, Verviers, Belgium), 0.01 M HEPES
bu¡er (Invitrogen), 0.2 mg/ml geneticin (G-418 sulfate) (Invitrogen)
and 1 Wg/ml puromycin (Sigma-Aldrich, St. Louis, MO, USA). The
cell cultures were maintained at 37‡C in a humidi¢ed, CO2-controlled
atmosphere and subcultivations were done every 2^3 days by diges-
tion of the monolayers with trypsin/EDTA (Invitrogen).
2.3. Antibody stainings and £ow cytometry
The antibodies used in this study were: PE-conjugated mouse anti-
human CD4 mAb clone SK3 (BD Biosciences, San Jose, CA, USA),
PE-conjugated rat anti-CXCR4 mAb clone 2B11 (BD Pharmingen,
San Diego, CA, USA), PE-conjugated mouse anti-human CXCR4
mAb clone 12G5 (BD Pharmingen), PE-conjugated mouse anti-hu-
man CXCR4 mAb clone 44717.111 (RpD Systems Europe, Abing-
don, UK), unconjugated mouse anti-human CXCR4 mAbs clones
44708.111 and 44716.111 (RpD Systems Europe) and PE-conjugated
goat anti-mouse IgG Ab (Caltag Laboratories, San Francisco, CA,
USA).
After trypsin digestion, CXCR4-transfected U87.CD4 cells were
incubated for at least 1 h at room temperature to allow re-expression
of receptor proteins at the cell surface. Then, 0.5U106 cells were
washed once with phosphate-bu¡ered saline (PBS) containing 2%
FBS, resuspended in 100 Wl PBS containing 2% FBS and incubated
with the appropriate antibody for 30 min on ice. Thereafter, the cells
were washed and, in case of an unlabelled primary antibody, incuba-
ted for 30 min on ice with the secondary antibody (diluted 1/100 in
PBS with 2% FBS). After ¢nal washing with PBS, the cell samples
were ¢xed in 1% paraformaldehyde in PBS and analyzed on a FACS-
can £ow cytometer (BD Biosciences Europe, Erembodegem, Belgium).
As a negative control for non-speci¢c background staining, the cells
were stained in parallel with Simultest Control Q1/Q2a (in case of di-
rectly labelled mAbs) (BD Biosciences) or with the secondary anti-
body alone (for the non-conjugated anti-CXCR4 mAbs 44708.111 and
44716.111).
2.4. HIV infection assays
The U87.CD4.CXCR4 transfectants were seeded in 24-well plates
(2U104 cells per well) and 1000 pg/ml p24 antigen (Ag) of the di¡er-
ent HIV-1 strains was added. The cytopathic e¡ect of virus replication
in the cell cultures (syncytium formation) was evaluated microscopi-
cally at day 5 after infection. Also, cell culture supernatants were
collected at day 5 and the HIV-1 core Ag p24 was quanti¢ed by
enzyme-linked immunosorbent assay (ELISA) (Perkin-Elmer, Boston,
MA, USA).
3. Results and discussion
3.1. Expression of the di¡erent CXCR4 mutants in stably
transfected cell lines
Stably transfected human astroglioma U87.CD4 cell lines,
expressing the di¡erent CXCR4 mutants (i.e. CXCR4[WT],
CXCR4[D171N], CXCR4[D262N], CXCR4[D171N,D262N],
CXCR4[D182N], CXCR4[D193N]), were established as de-
scribed previously [16]. Comparable CXCR4 mRNA expres-
sion in the di¡erent U87.CD4.CXCR4 transfectants was
ascertained by semi-quantitative reverse transcription poly-
merase chain reaction (data not shown). Adequate and com-
parable cell surface CXCR4 expression in the di¡erent cell
lines was demonstrated by £ow cytometry after staining
with the CXCR4-speci¢c mAb 2B11. This antibody recognizes
an epitope in the amino-terminal domain of human CXCR4
[24], which is not a¡ected by the mutations studied here. The
mean £uorescence intensities (MFI) for CXCR4-speci¢c stain-
ing were 41, 26, 58, 40, 52 and 39 for U87.CD4.CXCR4[WT],
U87.CD4.CXCR4[D171N], U87.CD4.CXCR4[D262N], U87.
CD4.CXCR4[D171N,D262N], U87.CD4.CXCR4[D182N]
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Fig. 1. Amino acid sequence and membrane organization of the chemokine receptor CXCR4 with indication of the positions of the mutated as-
partate residues.
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and U87.CD4.CXCR4[D193N] cells, respectively (Fig. 2,
black histograms). The MFI values for non-speci¢c back-
ground staining ranged between 3.6 and 4.7 (Fig. 2, white
histograms). Abundant cell surface expression of CD4, the
primary HIV receptor, was also con¢rmed by staining of
the di¡erent U87.CD4.CXCR4 transfectants with anti-human
CD4 mAb SK3, yielding MFI values between 144 and 260
(Fig. 2, gray histograms).
3.2. E¡ect of aspartate-to-asparagine mutation on antibody
recognition of CXCR4
HIV infectivity depends on the presence of CD4 and an
appropriate coreceptor. In addition, virus entry can be in£u-
enced by receptor concentration and potentially receptor con-
formation. It has indeed been shown that 7-TM receptors, like
CCR5 and CXCR4, can exist in antigenically distinct confor-
mations on certain cell types [25^27]. As a result, antibodies
targeted at conformation-dependent epitopes, such as the
most commonly used anti-CXCR4 mAb clone 12G5 [28],
may only recognize a subset of CXCR4 molecules expressed
at the cell surface [25]. Such conformational heterogeneity
may be of great importance in the context of studies examin-
ing the molecular interactions between HIV-1 Env and the
chemokine receptor. Therefore, we found it useful to evaluate
the antibody binding capacities of the di¡erent CXCR4 mu-
tants using a panel of four CXCR4-speci¢c mAbs, i.e. the
clones 12G5, 44708.111, 44716.111 and 44717.111. These
four antibodies are targeted at slightly di¡erent epitopes with-
in the second extracellular loop (ECL2) of the receptor pro-
tein, which is the area near the amino acid substitution sites
(Fig. 1). In contrast with the amino-terminal 2B11 mAb,
which showed comparable CXCR4 binding in all six trans-
fectants (Fig. 2, black histograms), marked di¡erences be-
tween the CXCR4 variants were observed with the ECL2
binding antibodies (Fig. 3). The CXCR4[D171N,D262N]
transfectant showed the lowest binding capacity for each of
the four distinct antibodies, while antibody reactivity was
partly decreased in the CXCR4[D171N] transfectant. The
D262N single mutation had no in£uence at all. The e¡ect of
the D193N substitution was most pronounced with the 12G5
and 44717.111 mAbs, the decrease in 12G5 mAb binding
capacity being comparable to that observed in the
CXCR4[D171N,D262N] transfectant. The CXCR4[D182N]
variant bound the mAbs 44708.111 and 44716.111 with equal
e⁄ciency as the wild-type, but showed a slightly reduced af-
¢nity for the 12G5 and 44717.111 mAbs (Fig. 3).
3.3. Coreceptor e⁄ciency of the CXCR4 mutants for diverse
HIV-1 strains
To ¢nd out whether the aspartate-to-asparagine substitu-
tions at positions 171, 262, 182 and 193 have any in£uence
on the capacity of CXCR4 to mediate HIV-1 entry, the di¡er-
ent CXCR4 transfectants were infected with the X4 HIV-1
strains NL4.3, IIIB and NDK, the dual-tropic R5/X4 HIV-1
strain HE, and the R5/X4 HIV-1 clinical isolate CI-10. The
virus-induced cytopathic e¡ect (syncytium formation) on the
cell cultures and the virus production, as measured by the p24
core Ag, were evaluated at day 5 after infection.
For HIV-1 NL4.3, p24 viral Ag productions varied 9 2-
fold among the CXCR4[WT], CXCR4[D171N], CXCR4-
[D182N] and CXCR4[D193N] transfectants within each indi-
vidual experiment. In contrast, NL4.3 virus replication was
severely impaired in the U87.CD4.CXCR4[D262N] cells, the
p24 Ag production being consistently v 15-fold lower than in
the wild-type CXCR4 transfectant (Fig. 4). In the NL4.3-in-
fected U87.CD4.CXCR4[D171N,D262N] cell culture, the p24
Ag concentration measured at day 5 did not exceed the initial
virus inoculum. Comparable observations were made with the
HIV-1 IIIB strain (Fig. 4). In accord with the p24 Ag mea-
surements, strong cytopathic e¡ects could be microscopically
observed at day 5 in the NL4.3- and IIIB-infected CXCR4-
[WT], CXCR4[D171N], CXCR4[D182N] and CXCR4-
Fig. 2. Flow cytometric analysis of the membrane expression of CD4 and CXCR4 in the stably transfected cell lines. The black histograms rep-
resent CXCR4-speci¢c staining by the 2B11 mAb, reacting with an epitope located in the amino-terminus of the receptor protein. The gray his-
tograms represent CD4-speci¢c staining by the SK3 mAb. The white histograms represent the background £uorescence due to non-speci¢c
binding of an isotypic control mAb. MFI values are presented in the text.
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[D193N] transfectants, while the extent of giant cell formation
was considerably reduced for both viruses in the U87.
CD4.CXCR4[D262N] cells, and no visible signs of virus
infection could be observed in U87.CD4.CXCR4-[D171N,
D262N] cells (data not shown). In accord with these ¢ndings,
CXCR4 structure^function studies by Brelot et al. also
pointed to the critical importance of Asp262 for the HIV co-
receptor activity of CXCR4 [29].
The D171N,D262N double mutation also seriously limited
the coreceptor e⁄ciency of CXCR4 for the R5/X4 HIV-1
clinical isolate CI-10; the CXCR4[D171N,D262N] transfec-
tant yielded a 25-fold lower p24 Ag level than the CXCR4-
[WT]-transfected cell line. However, unlike HIV-1 NL4.3 and
IIIB, the clinical isolate CI-10 replicated equally well in
U87.CD4.CXCR4[D262N] cells as in U87.CD4.CXCR4[WT]
cells, but slightly (V3-fold) less e⁄ciently in U87.CD4.
CXCR4[D171N] cells (Fig. 4).
A totally di¡erent pattern of viral replication was seen with
the X4 HIV-1 NDK strain [19]. This virus replicated with
comparably high e⁄ciency in the CXCR4[WT], CXCR4-
[D171N], CXCR4[D262N], CXCR4[D171N,D262N] and
CXCR4[D193N] transfectants, but was strongly a¡ected by
the D182N mutation, which caused a 20^40-fold reduction
in p24 Ag production (Fig. 4).
On the other hand, none of the mutations negatively in£u-
enced the coreceptor function of CXCR4 for the R5/X4 HIV-
1 strain HE. After 5 days of infection with the HE strain, no
signi¢cant reduction in viral replication could be observed
Fig. 3. Staining of the mutant CXCR4 transfectants with four di¡erent CXCR4-speci¢c mAbs, reacting with distinct epitopes located in ECL2.
The black curves represent CXCR4-speci¢c staining by the 12G5 mAb (left column), by the 44708.111 mAb (second column), by the 44716.111
mAb (third column), or by the 44717.111 mAb (right column). The MFI values for CXCR4-speci¢c staining are indicated in each histogram.
The white histograms represent the background £uorescence due to non-speci¢c binding of the secondary antibody (in the case of the
44708.111 and 44716.111 mAbs) or an irrelevant isotypic control mAb (in the case of the 12G5 and 44717.111 mAbs).
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either microscopically (data not shown) or by p24 Ag mea-
surements (Fig. 4), in any of the mutant CXCR4 transfec-
tants.
Interestingly, Wang et al. reported that conversion of one
single aspartate residue of CXCR4, i.e. Asp187, to a neutral
amino acid surprisingly unmasks reactivity with R5 viruses,
indicating that subtle changes in CXCR4 can dramatically
alter utilization by envelopes of varying tropism [30]. How-
ever, none of the CXCR4 mutants included in our study sup-
ported entry of the R5 HIV-1 strains BaL or ADA (data not
shown).
Our data indicate that the envelope gp120 glycoproteins of
distinct CXCR4-using HIV-1 strains and clinical isolates
largely di¡er in their dependence on speci¢c amino acid resi-
dues of CXCR4 for interaction with the chemokine receptor
and subsequent virus entry into the cells. Such diversity
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Fig. 4. Viral p24 Ag concentrations measured by ELISA in the culture supernatants of the mutant CXCR4 transfectants at day 5 after infec-
tion with the di¡erent HIV-1 strains. The data shown are from one representative experiment, which was repeated several times with compara-
ble results.
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among HIV strains in their structural requirements for func-
tional interaction with CXCR4 was previously reported by
Brelot et al. [29,31]. Also, Doranz et al. found that amino
acid residues in all four extracellular regions of CXCR4 con-
tribute to coreceptor activity, implying that the viral envelope
interacts with a conformationally complex structure of the
receptor protein [32]. Yet, AMD3100 is potently and consis-
tently active in the nanomolar range against every CXCR4-
using HIV-1 strain tested so far, including those viruses that
for their infectivity do not depend on the presence of aspartic
acid residues at positions 171 and/or 262 of the coreceptor
(e.g. NDK, HE, CI-10). This suggests that the inhibition of
virus entry by AMD3100 is not simply due to blockade of a
few individual amino acid residues. Presumably, AMD3100
holds the receptor protein in a rigid conformation that does
not allow the £exibility and structural rearrangements re-
quired for the productive interaction of gp120 with CXCR4
and the subsequent virus^cell fusion process.
3.4. Coreceptor e⁄ciency of the CXCR4 mutants for NL4.3
strains resistant to AMD3100, SDF-1 or dextran sulfate
Given the importance of Asp262 for both AMD3100 and
HIV-1 NL4.3 gp120 to interact with CXCR4, the question
arises whether or not an AMD3100-resistant variant of
NL4.3 would retain its dependence on this particular aspar-
tate residue. We have previously selected di¡erent NL4.3
strains resistant to either AMD3100 (NL4.3/AMD3100res)
[21], SDF-1 (NL4.3/SDF-1res) [22] or the virus binding inhib-
itor dextran sulfate (NL4.3/DSres) [23]. In MT-4 cells, NL4.3/
AMD3100res was V100-fold less sensitive to AMD3100, and
NL4.3/SDF-1res was V20-fold less sensitive to SDF-1 than
the wild-type virus. In addition, NL4.3/AMD3100res showed
partial cross-resistance to SDF-1 [33], and, vice versa, NL4.3/
SDF-1res also proved 10-fold less sensitive to AMD3100 than
the wild-type [22]. Importantly, like wild-type NL4.3, NL4.3/
AMD3100res was totally unable to use CCR5 as a coreceptor
(data not shown), indicating that resistance to AMD3100 is
not associated with a coreceptor switch to CCR5. Likewise,
Trkola et al. reported that a primary R5 isolate selected for
resistance against a CCR5-speci¢c small molecule inhibitor
remained totally dependent on CCR5 and failed to use
CXCR4 or any alternative coreceptor for cellular entry [34].
In contrast however, Mosier et al. have found that the
RANTES analogue, N-nonanoyl(NNY)-RANTES[2^68], po-
tently inhibits R5 HIV-1 replication in vivo in the human
peripheral blood lymphocyte-SCID mouse model, but under
certain experimental conditions rapidly selects for CXCR4-
using mutant viruses [35]. This observation underscores the
necessity to simultaneously block all signi¢cant viral corecep-
tors for an e¡ective anti-HIV therapy.
We have now examined the coreceptor e⁄ciency of the
di¡erent CXCR4 mutants for NL4.3/AMD3100res, NL4.3/
SDF-1res and NL4.3/DSres, as compared to wild-type NL4.3.
As shown in Fig. 4, AMD3100-resistant NL4.3 clearly ac-
quired the ability to use CXCR4[D262N] as a coreceptor,
whereas CXCR4[D171N,D262N] still failed to support virus
entry. Moreover, the D262N mutant also gained coreceptor
e⁄ciency for the SDF-1-resistant virus, as compared to wild-
type NL4.3. This is in agreement with the partial cross-resis-
tance of NL4.3/SDF-1res against AMD3100. In contrast, the
NL4.3 strain selected for resistance to dextran sulfate, which
does not speci¢cally interact with CXCR4 but blocks virus
adsorption to the cell membrane through interaction with
the positive charges on the viral gp120 [36], rather behaved
like the wild-type virus in our panel of CXCR4 mutants (Fig.
4). Thus, resistance of HIV-1 NL4.3 to AMD3100 is associ-
ated with a decreased dependence on Asp262, suggesting a
di¡erent mode of interaction of the AMD3100-resistant versus
wild-type NL4.3 gp120 with CXCR4. One possible explana-
tion could be that the envelope of the AMD3100-resistant
NL4.3 strain interacts with a di¡erent region of CXCR4.
However, as mentioned above, viruses that do not depend
on Asp262 of CXCR4 for their infectivity can still be blocked
by AMD3100, presumably through the conformational re-
straints imposed on the receptor protein upon binding of
the bicyclam. Therefore, we assume that the decreased suscep-
tibility of NL4.3/AMD3100res to AMD3100 results from an
increased ability/a⁄nity of the viral gp120 to interact with the
AMD3100-bound state of CXCR4. In this respect, it should
be noted that resistance to AMD3100 was only obtained after
a long-term selection process (s 60 passages), remained only
partial (V100-fold) and is based on an accumulation of mu-
tations in the gp120 glycoprotein, predominantly clustered in
the V3 loop [21]. In comparison, for certain anti-HIV drugs,
such as the non-nucleoside reverse transcriptase inhibitor
TSAO, s 1000-fold resistance resulting from a single point
mutation in the viral target enzyme can be achieved within
2^3 weeks [37].
3.5. Conclusion
In summary, we found that mutation of Asp262 of CXCR4
does not a¡ect antibody recognition of the receptor molecule
but has a large impact on its coreceptor function for HIV-1
viruses. Furthermore, our data point to the wide variation
among di¡erent viruses in their mode of interaction with the
chemokine receptor. Yet, the high-a⁄nity binding of the bi-
cyclam AMD3100 to Asp171 and Asp262 of CXCR4 has con-
formational consequences that a¡ect the HIV-1 coreceptor
function of CXCR4 in general, as X4 viruses that do not
require Asp262 as a CXCR4 interaction site are still e¡ectively
blocked by AMD3100. Apparently, the structural limitations
imposed on CXCR4 upon binding of AMD3100 cannot easily
be overcome by the emergence of resistant virus.
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